Research programme: microbiome-based therapeutics - DayTwo/Janssen Human Microbiome Institute/Weizmann Institute of Science

Drug Profile

Research programme: microbiome-based therapeutics - DayTwo/Janssen Human Microbiome Institute/Weizmann Institute of Science

Latest Information Update: 13 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator DayTwo; Disease Interception Accelerator; Janssen human microbiome institute; Weizmann Institute of Science
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Gestational diabetes; Metabolic disorders; Type 2 diabetes mellitus

Most Recent Events

  • 09 Feb 2017 Janssen Human Microbiome Institute, Janssen Disease Interception Accelerator, DayTwo and the Weizmann Institute of Science agree to develop mocrobiome-based therapeutics
  • 02 Feb 2017 Early research in Gestational diabetes in USA
  • 02 Feb 2017 Early research in Metabolic disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top